Keytruda OK'd as First-Line Tx in Advanced, Squamous NSCLC

(MedPage Today) -- Approved in combination with carboplatin and either paclitaxel or nab-paclitaxel
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news

Related Links:

Authors: Zhou HP, Tanaka R, Tsuji H Abstract A 49-year-old male presented with a three-day onset of blurred vision and metamorphopsia in the left eye. Fundoscopy and OCT images identified multiple subretinal masses with associating serous retinal detachment in both eyes. Bilateral choroidal metastasis was suspected, and further evaluation revealed a mass in the lower left lobe of the lung with multiple metastatic loci. Ultimately, the patient was diagnosed with Stage IVB (T2aN2M1c) adenocarcinoma of the lung. Genetic analysis revealed an exon 19 deletion mutation in the epidermal growth factor receptor (EGFR) gene....
Source: Ocular Immunology and Inflammation - Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research
In this study, a novel deep learning based variational method was proposed to automatically fuse multimodality information for tumor segmentation in PET/CT. A 3D fully convolutional network (FCN) was first designed and trained to produce a probability map from the CT image. The learnt probability map describes the probability of each CT voxel belonging to the tumor or the background, and roughly distinguishes the tumor from its surrounding soft tissues. A fuzzy variational model was then proposed to incorporate the probability map and the PET intensity image for an accurate multimodality tumor segmentation, where the proba...
Source: Neurocomputing - Category: Neuroscience Source Type: research
ConclusionsClinical staging modalities are reasonably accurate. However, less than half of Stage IIA-IIIA NSCLC patients receive guideline-concordant therapy which is associated with inferior survival. Identifying factors contributing to these differences is crucial to improve outcomes.Graphical abstract
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Yi-Cheng Gao, Xiong-Hui Zhou* and Wen Zhang* Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, China Due to the high heterogeneity and complexity of cancer, it is still a challenge to predict the prognosis of cancer patients. In this work, we used a clustering algorithm to divide patients into different subtypes in order to reduce the heterogeneity of the cancer patients in each subtype. Based on the hypothesis that the gene co-expression network may reveal relationships among genes, some communities in the network could influence the prognosis o...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Eleonora A. Braga1*†, Marina V. Fridman2†, Vitaly I. Loginov1,3, Alexey A. Dmitriev4 and Sergey G. Morozov1 1Institute of General Pathology and Pathophysiology, Moscow, Russia 2Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia 3Research Center of Medical Genetics, Moscow, Russia 4Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia Clear cell renal cell carcinoma (ccRCC) is the third most common urological cancer, and it has the highest mortality rate. The increasing drug resistance of metastatic ccRCC has resulted in the search f...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
ConclusionIn this study, concomitant mutations were found in 1.7% of the NSCLC. EGFR ‐TKI therapy was more effective than chemotherapy for patients harboringEGFR concomitant mutation, andROS1 concomitant mutations were more frequent in male patients. For patients harboring coalterations with anALK orROS1 rearrangement, we should be cautious when considering the therapeutic options.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
In this study, we mainly investigated the effects of antagonist for ghrelin-R (d-lys-3-GHRP-6) on conquering acquired gefitinib resistance in human lung cancer cells. We found that GHSR was overexpressed in our established HCC827/GR cells compared with parental cells, accompanied with increase of p-AKT and p-ERK1/2. Treatment ofd-lys-3-GHRP-6 significantly decreased p-AKT and p-ERK1/2 expression in HCC827/GR cells. H1650 cells and HCC827/GR cells were treated with control, gefitinib,d-lys-3-GHRP-6 andd-lys-3-GHRP-6  + gefitinib, respectively. In H1650 and HCC827/GR cells, combination ofd-lys-3-GHRP-6 and gefi...
Source: Human Cell - Category: Cytology Source Type: research
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic factors, incl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: The study indicates that secretory factors like TGF-β from neighboring endothelial cells may enhance expression of CD133 and impart an aggressive EMT phenotype to HBx-infected hepatoma cells in HBV induced HCC. Introduction Hepatocellular Carcinoma (HCC) is one of the most common cancer worldwide, representing approximately 4% of all malignancies (1). It has been estimated that more than 50% of HCC cases in the world are associated with hepatitis B virus (HBV) (2). HBV is a partially double stranded DNA virus belonging to the Hepadnavirus family. The HBV genome is 3.2 kb in size and contains four o...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: This study suggests a potential role for cfDNA for the early identification of lung cancer in patients with CT-detected pulmonary lesions. Importantly, a substantial number of somatic variants in healthy patients with benign pulmonary nodules were also found. Such “benign” variants, while largely unexplored to date, have widespread relevance to all liquid biopsies if cfDNA is to be used accurately for cancer detection. Introduction Lung cancer is the leading cause of cancer-related death in the United States (1). Most patients present with advanced disease with limited cure potential. The N...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Non-Small Cell Lung Cancer | Respiratory Medicine